TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26845273
Drug: Antipsychotic monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic monotherapy (APM)
Study: 12490031
Drug: Simulated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated treatment
Study: 1959859
Drug: Parenteral amino
Normalized name: parenteral amino acid 7 % comb no.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral amino acid administration (2 l/day of a solution of dextrose (65 gm/L) and amino acids (25.8 gm/L) for 1 month)
Study: 1959859
Drug: Control (dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (dextrose solution only)
Study: 27572830
Drug: TAK-063 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-063 (1000 mg)
Study: 27572830
Drug: TAK-063 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-063 (100 mg) under fed conditions
Study: 27572830
Drug: TAK-063 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-063 (various doses)
Study: 21909815
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of batroxobin and TXA (group D)
Study: 17663820
Drug: Insulin enteric-coated
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin enteric-coated soft capsules (50 IU)
Study: 17663820
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (15 IU)
Study: 8211801
Drug: Theopek taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theopek taken twice daily
Study: 8211801
Drug: Euphylong taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euphylong taken in a single daily dose
Study: 3082230
Drug: metrifonate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: metrifonate (10 mg/kg body weight, twice)
Study: 3082230
Drug: oxamniquine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxamniquine (60 mg/kg)
Study: 31835620
Drug: Zanthoxylum armatum
Normalized name: ZANTHOXYLUM ARMATUM FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanthoxylum armatum (ZA) extract (single dose on Day 1)
Study: 24473958
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion group (CIG)
Study: 24473958
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion group (IIG)
Study: 16525751
Drug: Yogurt (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt (375 g/d)
Study: 16525751
Drug: Semi-skimmed milk
Normalized name: Calcium fortified semi-skimmed milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-skimmed milk (400 ml/d)
Study: 9684746
Drug: Ubiquinone supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinone supplementation (180 mg daily)
Study: 31421838
Drug: Thermal ablation
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal ablation (radiofrequency ablation and endovenous laser therapy)
Study: 6635761
Drug: Praziquantel 25
Normalized name: PRAZIQUANTEL 25 kg in 25 kg POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 25 mg/kg
Study: 19921358
Drug: Intrathecal injection
Normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal injection of 0.5% isobaric bupivacaine, 2.8 ml plus morphine, 0.05 mg (Group B)
Study: 19921358
Drug: Intrathecal injection
Normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal injection of 0.5% isobaric bupivacaine, 2.8 ml (Group A)
Study: 15041008
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia with Xylocain solution
Study: 9066031
Drug: Liquid combination
Normalized name: liquid paraffin, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid combination of DTP-PRP-T vaccine
Study: 22135493
Drug: Routine pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine pharmacological treatment (Control)
Study: 16267842
Drug: Piribedil 150
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil 150 mg/day
Study: 29802820
Drug: 400g red
Normalized name: Red gum
DrugBank: Eucalyptus gum (DB15537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400g red raspberries (403 mg total (poly)phenols)
Study: 23479592
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg lycopene/day
Study: 21130359
Drug: Acupuncture as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture as an adjunct therapy
Study: 14608833
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg daily for 6 months
Study: 12221217
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (SP) 40 g daily for 3 months
Study: 12629084
Drug: Milk-based protein
Normalized name: milk protein concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-based protein (MBP) 40 g daily for 3 months
Study: 12080805
Drug: L-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine supplementation (15 g daily)
Study: 12080805
Drug: Glycine supplementation
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine supplementation (25 g daily)
Study: 8649051
Drug: ATRA (all-trans
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATRA (all-trans retinoic acid) plus chemotherapy
Study: 1754467
Drug: IVIgG 400
Normalized name: IVIgGM
DrugBank: Pentaglobin (DB15865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIgG 400 mg/kg b.w. on 5 consecutive alternate days and subsequently after 15 days and monthly thereafter for up to six months (group B)
Study: 1754467
Drug: CyA 5‐10/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA 5‐10/kg b.w. by mouth in two daily doses for a period between 6 and 18 months (group C)
Study: 6626436
Drug: diclofensine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofensine 50 mg
Study: 6626436
Drug: diclofensine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofensine 25 mg
Study: 3921328
Drug: Simethicone (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone (two tablets)
Study: 6813959
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets)
Study: 30893070
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid supplement
Study: 26047963
Drug: High flavanol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flavanol drink (494 mg)
Study: 16579996
Drug: Goserelin 10.8
Normalized name: goserelin 10.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 10.8 mg administered 24 hours after UAE
Study: 3780284
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg betahistine dihydrochloride
Study: 18455082
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg daily for 7 years)
Study: 18455082
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 7 years)
Study: 16647439
Drug: Contrast medium
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast medium administration during donor evaluation (coronary angiography or levography)
Study: 16647439
Drug: No contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: No contrast medium administration during donor evaluation
Study: 9178844
Drug: Ketamine (0.83
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.83 mg/ml, 6 ml)
Study: 1389240
Drug: Cefuroxime (CFX)
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime (CFX) 1.5 g and metronidazole (MTR) 1.0 g at induction of anaesthesia (Group C)
Study: 1389240
Drug: Cefuroxime (CFX)
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime (CFX) 1.5 g on induction of anaesthesia (Group D)
Study: 1389240
Drug: Cefuroxime (CFX)
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime (CFX) 1.5 g on induction of anaesthesia then CFX 750 mg bd for 2 days (Group E)
Study: 3901631
Drug: Hemosorption treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemosorption treatment (n=90)
Study: 3901631
Drug: No hemosorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hemosorption treatment (n=50)
Study: 18279877
Drug: Delayed oral
Normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed oral intake (DOI) group - clear liquid drink given 8 hours after surgery
Study: 18279877
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral intake (EOI) group
Study: 18279877
Drug: Delayed oral
Normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed oral intake (DOI) group
Study: 17302256
Drug: Interferon plus
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon plus ribavirin therapy
Study: 12898010
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg B2036‐PEG
Study: 12898010
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg B2036‐PEG
Study: 11885185
Drug: Hydroxyapatite (HA)-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyapatite (HA)-coated implants
Study: 6419593
Drug: Auranofin, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin, 3 mg twice daily
Study: 3903735
Drug: No dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dietary change after withdrawal from drugs (Group II)
Study: 3903735
Drug: Continued drug
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued drug treatment (Group III)
Study: 22749332
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral suctioning (COS) using a saliva ejector connected to 100mmHg of suction.
Study: 22749332
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral suctioning (COS) using a saliva ejector.
Study: 17222282
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of abstinence achieved during treatment
Study: 9247454
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IL-10 (0.5, 1, 5, 10, or 25 micrograms/kg) administered once daily by intravenous bolus injection over 7 consecutive days
Study: 9247454
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once daily by intravenous bolus injection over 7 consecutive days
Study: 6452806
Drug: Zimelidine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimelidine 100 mg (divided dose)
Study: 29256407
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium lactate (360 mg elemental magnesium)
Study: 9266953
Drug: Glycosylated G-CSF
Normalized name: Glycosylated recombinant G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycosylated G-CSF (5 microg/kg/d)
Study: 8345034
Drug: CGS 20
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 20 267 (0.02 mg to 30 mg)
Study: 8345034
Drug: CGS 20
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 20 267 (0.02 mg)
Study: 8345034
Drug: CGS 20
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 20 267 (30 mg)
Study: 8345034
Drug: CGS 20
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 20 267 (10 mg and 30 mg)
Study: 8345034
Drug: CGS 20
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 20 267 (up to 30 mg)
Study: 8345034
Drug: CGS 20
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 20 267 (all doses)
Study: 27562916
Drug: Exenatide (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (acute infusion)
Study: 10356074
Drug: 500 microgram
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microgram folic acid tablet taken with 100 g wheat bran cereal (high folate control)
Study: 31237871
Drug: Azithromycin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (20 mg/kg oral suspension)
Study: 21570139
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration oxygen at 15 L/min via a non-rebreather mask
Study: 21570139
Drug: Air at
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air at 15 L/min via a non-rebreather mask
Study: 9850350
Drug: Continuous NaF
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous NaF 50 mg/day with calcium 2000 mg/day for a mean of 15 months (10 with vitamin D, 16 without)
Study: 9850350
Drug: Cyclical low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclical low-dose NaF alternating with vitamin D for a mean of 15 months and total treatment duration of 28 months
Study: 4947494
Drug: Isoniazid 400
Normalized name: isoniazid 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 400 mg daily for 1 year (second year maintenance) in patients with residual cavitation.
Study: 25326090
Drug: Darunavir/ritonavir 600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir 600/100 mg twice daily (n=6)
Study: 25326090
Drug: Darunavir/ritonavir 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir 800/100 mg once daily (n=17)
Study: 25326090
Drug: Darunavir/ritonavir 600/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir 600/100 mg once daily (n=1)
Study: 21173171
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) concentrations (ng/mL)
Study: 30268470
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus cisplatin combination therapy
Study: 15760536
Drug: Cranial hypothermia
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial hypothermia treatment started within 6 hours (Group A)
Study: 2651251
Drug: Molsidomine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (2 x 2 mg)
Study: 319871
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol (4 mug/kg)
Study: 23511682
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL of contrast medium (Group A)
Study: 23511682
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of contrast medium (Group B)
Study: 23511682
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of contrast medium (Group C)
Study: 15312252
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day of isosorbide mononitrate (ISMO)
Study: 15312252
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day of isosorbide mononitrate (ISMO)
Study: 30518633
Drug: Tumor-infiltrating lymphocyte
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor-infiltrating lymphocyte (TIL) therapy
Study: 24480603
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (moderate pressure stroking)
Study: 20228679
Drug: Intravenous glucagon‐like
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucagon‐like peptide‐1 (1.2 pmol/kg/min)
Study: 16088097
Drug: Ethanol +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol + honey (0.5 g/kg + 1.25 ml/kg)
Study: 363255
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy to the regional lymph node area following lymphadenectomy
Study: 19672567
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/day (n=13)
Study: 17088163
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care for depression (12 months of systematic depression care including antidepressant pharmacotherapy and/or problem-solving treatment)
Study: 7869886
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) 300 mg.kg‐1
Study: 7869886
Drug: NaCl 207
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 207 mg.kg‐1
Study: 3257532
Drug: Sulfamethoxazole and
Normalized name: sulfamethoxazole and trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfamethoxazole and trimethoprim (800 mg and 160 mg twice per day)
Study: 28615258
Drug: Package of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Package of health and nutrition interventions (lipid nutrient supplement, deworming medication, zinc supplementation, bed net, malaria chemoprophylaxis)
Study: 25783161
Drug: Beclomethasone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone (40 μg twice daily)
Study: 21410628
Drug: Linagliptin plus
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin plus pioglitazone (30 mg pioglitazone plus 5 mg linagliptin)
Study: 12673681
Drug: Peptide MAGE‐A12:170‐178
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide MAGE‐A12:170‐178 administered subcutaneously in incomplete Freund's adjuvant (IFA), either every week or every 3 weeks for 4 cycles.
Study: 10780138
Drug: Telephone-administered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered cognitive-behavioral therapy (CBT) - Coping with MS (CMS)
Study: 8776821
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) 30 mg intravesical instillations weekly for 8 weeks, followed by monthly maintenance doses for 12 months
Study: 29880238
Drug: Amisulpride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (100 mg daily)
Study: 29880238
Drug: Amisulpride (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride (continued treatment)
Study: 17036029
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin 1 mg/kg every 8 h
Study: 9156785
Drug: TCV-309 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCV-309 (1.0 mg/kg twice daily for 7 days)
Study: 6240787
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of spectinomycin intramuscularly
Study: 6240787
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g of thiamphenicol (500 mg intramuscularly after oral 2 g)
Study: 29424731
Drug: Cardiac shock
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac shock wave therapy (CSWT)
Study: 18833117
Drug: Piracetam as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam as a monotherapy in daily dosage 50‐70 mg/kg for 6 weeks
Study: 18833117
Drug: No pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacological therapy
Study: 11921128
Drug: Suspension (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension (2.5 mg doses)
Study: 9885797
Drug: Ondansetron (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (acute treatment)
Study: 9885797
Drug: Ondansetron (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (chronic administration)
Study: 22320335
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of availability, labeling, and price reduction
Study: 11593992
Drug: Press-coated, time-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Press-coated, time-controlled release tablets containing pseudoephedrine hydrochloride
Study: 9519217
Drug: Hypo-osmolar aerosol
Normalized name: polyethylene glycols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypo-osmolar aerosol (ultrasonically nebulized distilled water, output 2 ml/min-1)
Study: 7863140
Drug: Vaginal application
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal application of Lactobacillus casei v. rhamnosus twice weekly
Study: 23447696
Drug: Dihydroartemisinin-piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DP) treatment
Study: 23447696
Drug: Dihydroartemisinin-piperaquine (DP)
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine (DP) treatment with TMP-SMX prophylaxis
Study: 18216764
Drug: Remi-1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remi-1 group (1 ng x mL(‐1) remifentanil)
Study: 18216764
Drug: Remi-2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remi-2 group (2 ng x mL(‐1) remifentanil)
Study: 18216764
Drug: Remi-3 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remi-3 group (3 ng x mL(‐1) remifentanil)
Study: 18216764
Drug: Remi-4 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remi-4 group (4 ng x mL(‐1) remifentanil)
Study: 11101061
Drug: rhuIL-10 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuIL-10 1 microg/kg daily